1.Qi, L.Y.; Wang, Y.; Hu, L.F.; Zhao, P.S.; Yu, H.Y.; Xing, L.; Gao, X.D.*; Cao, Q.R.*; Jiang, H.L.* Enhanced nuclear gene delivery via integrating and streamlining intracellular pathway. J Control Release. 2022;341:511-23. (IF: 11.467)
2.Wang, Y.; Hu, L.F.; Cui, P.F.; Qi, L.Y.; Xing. L.*; Jiang, H.L.* Pathologically responsive mitochondrial gene therapy in an allotopic expression-independent manner cures Leber’s hereditary optic neuropathy. Adv Mater. 2021;33:2103307. (IF: 30.849)
3.Zhou, T.J.; Xu, Y.; Xing. L.; Wang, Y.; Jiang, H.L.* A harmless-harmful switchable and uninterrupted laccase-instructed killer for activatable chemodynamic therapy. Adv Mater. 2021;33:2100114. (IF: 30.849)
4.Wang, Y.; Hu, L.F.; Zhou, T.J.; Qi, L.Y.; Xing, L.; Lee, J.; Wang, F.Z.; Oh, Y.K.*; Jiang, H.L.* Gene therapy strategies for rare monogenic disorders with nuclear or mitochondrial gene mutations. Biomaterials. 2021;277:121108. (IF: 12.479)
5.Xing, L.; Liu, X.Y.; Zhou, T.J.; Wan, X.; Wang, Y.; Jiang, H.L.* Photothermal nanozyme-ignited Fenton reaction-independent ferroptosis for breast cancer therapy. J Control Release. 2021;339:14-26. (IF: 9.776)
6.Xing, L.; Yang, C.X.; Zhao, D.; Shen, L.J.; Zhou, T.J.; Bi, Y.Y.; Huang, Z.J.; Wei, Q.; Li, L.*; Li, F.*; Jiang, H.L.* A carrier-free anti-inflammatory platinum (II) self-delivered nanoprodrug for enhanced breast cancer therapy. J Control Release. 2021;331:460-471. (IF: 9.776)
7.Chang, X.; Xing, L.; Wang, Y.; Yang, C.X.; He, Y.J.; Zhou, T.J.; Gao, X.D.; Li. L.; Hao. H.P.*; Jiang, H.L.* Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis. Sci Adv. 2020;6:eaba3167, (IF: 13.116)
8.He, Y.J.; Liu, X,Y.; Xing, L.; Wan, Xing.; Chang, X.; Jiang, H.L.* Fenton reaction-independent ferroptosis therapy via glutathione and iron redox couple sequentially triggered lipid peroxide generator. Biomaterials. 2020;241:119911. (IF: 10.317)
9.Fan, Q.Q.; Zhang, C.L.; Qiao, J.B.; Cui, P.F.; Xing, L.; Oh, Y.K.*; Jiang, H.L.* Extracellular matrix-penetrating nanodrill micelles for liver fibrosis therapy. Biomaterials. 2020;230:119616. (IF: 10.317)
10.Xing, L.; Gong, J.H.; Wang, Y.;, Zhu, Y.; Huang, Z.J.; Zhao, J.; Li, F.; Wang, J.H.*; Wen, H.*; Jiang, H.L.* Hypoxia alleviation-triggered enhanced photodynamic therapy in combination with IDO inhibitor for preferable cancer therapy. Biomaterials. 2019;206:170-182. (IF: 10.273)
11.Fan, Y.T.; Zhou, T.J.; Cui, P.F.; He, Y.J.; Chang, X.; Xing, L.*; Jiang, H.L.* Modulation of intracellular oxygen pressure by dual-drug nanoparticles to enhance photodynamic therapy. Adv Funct Mater. 2019;29,10:1806708. (IF: 15.621)
Prof. Jiang has made prominent contributions to the establishment of biocompatible nano-delivery system for the facilitated stability and pharmaceutical activity of protein drugs. Besides, he has greatly promoted the initiation and development of modified chitosan-based gene delivery system, as well as the establishment of safe and effective gene delivery systems with multiple functions.
1.Qi, L.Y.; Wang, Y.; Hu, L.F.; Zhao, P.S.; Yu, H.Y.; Xing, L.; Gao, X.D.*; Cao, Q.R.*; Jiang, H.L.* Enhanced nuclear gene delivery via integrating and streamlining intracellular pathway. J Control Release. 2022;341:511-23. (IF: 11.467)
2.Wang, Y.; Hu, L.F.; Cui, P.F.; Qi, L.Y.; Xing. L.*; Jiang, H.L.* Pathologically responsive mitochondrial gene therapy in an allotopic expression-independent manner cures Leber’s hereditary optic neuropathy. Adv Mater. 2021;33:2103307. (IF: 30.849)
3.Zhou, T.J.; Xu, Y.; Xing. L.; Wang, Y.; Jiang, H.L.* A harmless-harmful switchable and uninterrupted laccase-instructed killer for activatable chemodynamic therapy. Adv Mater. 2021;33:2100114. (IF: 30.849)
4.Wang, Y.; Hu, L.F.; Zhou, T.J.; Qi, L.Y.; Xing, L.; Lee, J.; Wang, F.Z.; Oh, Y.K.*; Jiang, H.L.* Gene therapy strategies for rare monogenic disorders with nuclear or mitochondrial gene mutations. Biomaterials. 2021;277:121108. (IF: 12.479)
5.Xing, L.; Liu, X.Y.; Zhou, T.J.; Wan, X.; Wang, Y.; Jiang, H.L.* Photothermal nanozyme-ignited Fenton reaction-independent ferroptosis for breast cancer therapy. J Control Release. 2021;339:14-26. (IF: 9.776)
6.Xing, L.; Yang, C.X.; Zhao, D.; Shen, L.J.; Zhou, T.J.; Bi, Y.Y.; Huang, Z.J.; Wei, Q.; Li, L.*; Li, F.*; Jiang, H.L.* A carrier-free anti-inflammatory platinum (II) self-delivered nanoprodrug for enhanced breast cancer therapy. J Control Release. 2021;331:460-471. (IF: 9.776)
7.Chang, X.; Xing, L.; Wang, Y.; Yang, C.X.; He, Y.J.; Zhou, T.J.; Gao, X.D.; Li. L.; Hao. H.P.*; Jiang, H.L.* Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis. Sci Adv. 2020;6:eaba3167, (IF: 13.116)
8.He, Y.J.; Liu, X,Y.; Xing, L.; Wan, Xing.; Chang, X.; Jiang, H.L.* Fenton reaction-independent ferroptosis therapy via glutathione and iron redox couple sequentially triggered lipid peroxide generator. Biomaterials. 2020;241:119911. (IF: 10.317)
9.Fan, Q.Q.; Zhang, C.L.; Qiao, J.B.; Cui, P.F.; Xing, L.; Oh, Y.K.*; Jiang, H.L.* Extracellular matrix-penetrating nanodrill micelles for liver fibrosis therapy. Biomaterials. 2020;230:119616. (IF: 10.317)
10.Xing, L.; Gong, J.H.; Wang, Y.;, Zhu, Y.; Huang, Z.J.; Zhao, J.; Li, F.; Wang, J.H.*; Wen, H.*; Jiang, H.L.* Hypoxia alleviation-triggered enhanced photodynamic therapy in combination with IDO inhibitor for preferable cancer therapy. Biomaterials. 2019;206:170-182. (IF: 10.273)
11.Fan, Y.T.; Zhou, T.J.; Cui, P.F.; He, Y.J.; Chang, X.; Xing, L.*; Jiang, H.L.* Modulation of intracellular oxygen pressure by dual-drug nanoparticles to enhance photodynamic therapy. Adv Funct Mater. 2019;29,10:1806708. (IF: 15.621)
